Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 5/20 | 0.52 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.47 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.46 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.46 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CCR8 | P51685 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL159259 | 0.99 | L3MBTL1 (0.54) | L3MBTL1ATMTACR1ALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL1621693 | 0.89 | ALDH1A1 (0.56) | L3MBTL1ATMALDH1A1MEN1KMT2A | |
| SCHEMBL1622710 | 0.88 | ALDH1A1 (0.57) | L3MBTL1ATMALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL719130 | 0.88 | TACR1 (0.54) | TACR1SIGMAR1CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL183705 | 0.88 | ALDH1A1 (0.51) | L3MBTL1ATMALDH1A1MEN1KMT2A | |
| SCHEMBL31351576 | 0.88 | KDM4E (0.66) | L3MBTL1ATMALDH1A1MEN1KMT2A | |
| SCHEMBL4948411 | 0.87 | MEN1 (0.54) | L3MBTL1ATMTACR1ALDH1A1MEN1 | |
| SCHEMBL183706 | 0.86 | ALDH1A1 (0.52) | L3MBTL1ATMALDH1A1MEN1KMT2A | |
| SCHEMBL1339973 | 0.86 | TACR1 (0.53) | TACR1SIGMAR1CHRM2CHRM4CHRM5 | |
| SCHEMBL30994721 | 0.86 | TACR1 (0.53) | TACR1SIGMAR1CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059870-A | Synthesis method of N-Boc-4-oxo-3-piperidinecarboxylic acid ethyl ester | 苏州敬业医药化工有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-105237037-A | Water-proofing agent for natural stone building | YANTAI SHUNLONG CHEMICAL ENGINEERING TECHNOLOGY CO LTD | 2016-01-13 | — | — | CN | claimed |
| US-20050065164-A1 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | WOCKHARDT LIMITED | 2005-03-24 | — | — | US | claimed |
| US-20030216568-A1 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation,compositions and use as medicaments | WOCKHARDT LIMITED | 2003-11-20 | — | — | US | claimed |
| CN-122059870-A | Synthesis method of N-Boc-4-oxo-3-piperidinecarboxylic acid ethyl ester | 苏州敬业医药化工有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-3806853-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | ONCO3R THERAPEUTICS BV (BE) | 2026-03-18 | — | — | EP | disclosed |
| US-12509438-B2 | Pyrazole derivative | APTABIO THERAPEUTICS INC. (KR) | 2025-12-30 | — | — | US | disclosed |
| US-12264156-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2025-04-01 | — | — | US | disclosed |
| CN-118359612-A | Compounds and pharmaceutical compositions for the treatment of diseases | 加拉帕戈斯股份有限公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-3630116-B1 | TETRAHYDROPYRIDO[4,3-D]PYRIMIDINE INHIBITORS OF ATR KINASE | UNIV TEXAS (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-112292129-B | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | 加拉帕戈斯股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023237580-A1 | TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2023-12-14 | — | — | WO | disclosed |
| US-6251902-B1 | Dipeptide derivatives as growth hormone secretagogues | PFIZER INC. | 2001-06-26 | — | — | US | disclosed |
| WO-2000059510-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-1001970-A1 | DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES | PFIZER INC. (US) | 2000-05-24 | — | — | EP | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998058947-A1 | DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES | PFIZER INC. (US) | 1998-12-30 | — | — | WO | disclosed |
| US-5760050-A | SCHIZOPHRENIA | WARNER-LAMBERT COMPANY (US) | 1998-06-02 | — | — | US | disclosed |
| EP-0087280-A2 | 3-(2-Mono-and dialkylamino)propyl(-1,2,3,4-tetrahydro-5H-(1) benzopyrano(3,4-c)pyridin-5-ones and derivatives thereof, a process for their production, and pharmaceutical compositions containing such compounds | WARNER-LAMBERT COMPANY (US) | 1983-08-31 | — | — | EP | disclosed |
| US-4382939-A | 3-[2-(Mono-and dialkylamino)propyl]-1,2,3,4-tetrahydro-5H-[1]benzopyrano[3,4-C]pyridin-5-ones useful for treating bronchospastic diseases | WARNER LAMBERT COMPANY (US) | 1983-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065164-A1 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | ABCG2, CYP3A7, UGT1A7 | TACR1 1776/4885SIGMAR1 913/4885CHRM2 4530/4885 |
| US-12264156-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | TNF, IL1A, COL1A1 | TACR1 1010/4885SIGMAR1 2162/4885CHRM2 1466/4885 |
| US-12509438-B2 | Pyrazole derivative | CBR3, NR3C2, NR3C1 | TACR1 1519/4885SIGMAR1 153/4885CHRM2 142/4885 |
| US-20030216568-A1 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation,compositions and use as medicaments | ABCG2, CYP3A7, UGT1A7 | TACR1 1776/4885SIGMAR1 913/4885CHRM2 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.